News | June 18, 2026
Moderna reshapes leadership and ops model as it pushes into oncology, rare disease
CEO Stéphane Bancel framed the changes as essential to scaling the business
CEO Stéphane Bancel framed the changes as essential to scaling the business
Mahler brings more than 20 years of leadership experience spanning cell therapy, biopharmaceutical development, manufacturing, and global business management
Leading experts from AIIMS Kalyani, Syngene, Veeda Lifesciences, Lambda Therapeutic, DNDi, JSS Medical, KIHT, InoRx, ISCR and SIRO Clintech to discuss India’s readiness as preferred clinical research destination
Report reveals growing confidence in AI-driven decision-making, but highlights persistent challenges in scaling digital investments and converting innovation into measurable business value
Since 2022, we have grown threefold and our growth story is built on scale, scientific innovation and deep customer partnerships
Collaboration integrates MERCURIUS DRUG-seq technologies with Revvity’s screening portfolio, enabling scalable transcriptomic profiling for next-generation drug discovery and AI-driven research
From a $10 billion bioeconomy to over $190 billion, indigenous CAR-T therapy, and a booming startup ecosystem highlight 12 years of transformation in India’s science and technology landscape
MabionCD20 is a monoclonal antibody originally developed by Mabion as a biosimilar candidate to MabThera and Rituxan therapies
Phase 1 study to evaluate Siglec-6-targeted CAR-T therapy in relapsed or refractory AML and CLL patients, marking a major milestone for T-CURX’s scalable non-viral CAR-T platform
Both nations deepen cooperation in health innovation, AI-driven healthcare, biomedical research, data sharing, and life sciences to accelerate next-generation healthcare solutions
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
